Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Nov. 30, 2019	Jan. 09, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-Q
Document Period End Date	Nov. 30, 2019
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		17,735,775
Entity File Number	000-50298
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Nov. 30, 2019	Aug. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 3,171	$ 3,329
Short-term deposits	23,755	25,252
Marketable securities	3,207	3,701
Prepaid expenses and other current assets	609	1,042
Total current assets	30,742	33,324
LONG-TERM ASSETS:
Long-term deposits	1	1
Marketable securities	250	1,295
Amounts funded in respect of employee rights upon retirement	16	19
Property and equipment, net	27	24
Operating lease right of use assets	106
Total long-term assets	400	1,339
Total assets	31,142	34,663
CURRENT LIABILITIES:
Accounts payable and accrued expenses	1,796	2,541
Deferred revenues	2,703	2,703
Payable to related parties	96	64
Operating lease liabilities	46
Total current liabilities	4,641	5,308
LONG-TERM LIABILITIES:
Deferred revenues	8,983	9,658
Employee rights upon retirement	17	22
Provision for uncertain tax position	11	11
Operating lease liabilities	60
Other liabilities	270	271
Total long-term liabilities	9,341	9,962
COMMITMENTS (note 2)
STOCKHOLDERS' EQUITY:
Common stock, $0.012 par value (30,000,000 authorized shares; 17,400,612 and 17,383,359 shares issued and outstanding as of November 30, 2019 and August 31, 2019, respectively)	209	208
Additional paid-in capital	100,597	100,288
Accumulated deficit	(83,646)	(81,103)
Total stockholders' equity	17,160	19,393
Total liabilities and stockholders' equity	$ 31,142	$ 34,663

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Nov. 30, 2019	Aug. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	17,400,612	17,383,359
Common stock, shares outstanding	17,400,612	17,383,359

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
Income Statement [Abstract]
REVENUES	$ 674	$ 674
COST OF REVENUES		35
RESEARCH AND DEVELOPMENT EXPENSES	2,022	4,347
GENERAL AND ADMINISTRATIVE EXPENSES	1,081	932
OPERATING LOSS	2,429	4,640
FINANCIAL INCOME	209	286
FINANCIAL EXPENSES	20	8
INCOME (LOSS) FROM CHANGES IN FAIR VALUE OF INVESTMENTS	(303)	60
NET LOSS FOR THE PERIOD	$ 2,543	$ 4,302
LOSS PER SHARE OF COMMON STOCK:
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$ 0.15	$ .25
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	17,472,315	17,448,744

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands

Common Stock

Additional paid-in capital

Accumulated other comprehensive income

Accumulated deficit

Total

BALANCE at Aug. 31, 2018

$ 207

$ 99,426

$ 702

$ (69,223)

$ 31,112

BALANCE, Shares at Aug. 31, 2018

17,369

INITIAL ADOPTION OF ASC 606

1,773

INITIAL ADOPTION OF ASU 2016-01

(702)

702

CHANGES DURING THE THREE MONTH PERIOD ENDED

SHARES ISSUED FOR SERVICES

^[1]

SHARES ISSUED FOR SERVICES, Shares

STOCK-BASED COMPENSATION

^[1]

239

STOCK-BASED COMPENSATION, Shares

NET LOSS

(4,302)

BALANCE at Nov. 30, 2018

$ 207

99,701

(71,050)

28,858

BALANCE, Shares at Nov. 30, 2018

17,377

BALANCE at Aug. 31, 2019

$ 208

100,288

(81,103)

19,393

BALANCE, Shares at Aug. 31, 2019

17,383

CHANGES DURING THE THREE MONTH PERIOD ENDED

SHARES ISSUED FOR SERVICES

^[1]

SHARES ISSUED FOR SERVICES, Shares

EXERCISE OF WARRANTS AND OPTIONS

$ 1

EXERCISE OF WARRANTS AND OPTIONS, Shares

STOCK-BASED COMPENSATION

^[1]

280

STOCK-BASED COMPENSATION, Shares

NET LOSS

(2,543)

BALANCE at Nov. 30, 2019

$ 209

$ 100,597

$ (83,646)

$ 17,160

BALANCE, Shares at Nov. 30, 2019

17,400

[1]	Represents an amount of less than $1.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2019	Nov. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,543)	$ (4,302)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation		2
Exchange differences and interest on deposits and held to maturity bonds	(92)	(116)
Changes in fair value of investments	303	(60)
Stock-based compensation	280	239
Shares issued for services	17	36
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	433	(153)
Accounts payable, accrued expenses and related parties	(714)	929
Contract liabilities	(675)	(674)
Liability for employee rights upon retirement	(5)
Other liabilities		(32)
Total net cash used in operating activities	(2,996)	(4,131)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term deposits	(3,000)
Purchase of held to maturity securities		(397)
Proceeds from sale of short-term deposits	4,600	3,000
Proceeds from maturity of held to maturity securities	1,225	400
Funds in respect of employee rights upon retirement	3
Purchase of property and equipment	(3)	(8)
Total net cash provided by investing activities	2,825	2,995
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs	1
Proceeds from exercise of options	12
Total net cash provided by financing activities	13
EFFECT OF EXCHANGE RATE CHANGES ON CASH	0	1
DECREASE IN CASH AND CASH EQUIVALENTS	(158)	(1,135)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,329	4,996
CASH AND CASH EQUIVALENTS AT END OF PERIOD	3,171	3,861
SUPPLEMENTARY DISCLOSURE ON CASH FLOWS -
Interest received	$ 112	$ 159

Significant Accounting Policies

3 Months Ended

Nov. 30, 2019

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Incorporation and operations

Oramed Pharmaceuticals Inc. (collectively with its subsidiary, the “Company”, unless the context indicates otherwise) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. to acquire the provisional patent related to an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On July 30, 2019, the Subsidiary incorporated a wholly-owned subsidiary in Hong Kong, Oramed HK Limited. As of November 30, 2019, Oramed HK Limited has no operations.

On November 30, 2015, the Company entered into a Technology License Agreement with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “License Agreement”). According to the License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People's Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the "Product"). Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.

The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product in the Territory, and ending upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in the Territory (the "Royalty Term").

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

Among others, the Company's involvement through the product submission date will include consultancy for the pre-commercialization activities in the Territory, as well as advisory services to HTIT on an ongoing basis.

As of November 30, 2019, the Company has received milestone payments in an aggregate amount of $20,500 as follows: the initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016, the fourth milestone payment of $4,000 was received in October 2016 and the fifth milestone payment of $3,000 was received in January 2019.

In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement with HTIT (the “SPA”). According to the SPA, the Company issued 1,155,367 shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015.

In July 2015, according to the letter of intent signed between the parties or their affiliates, HTIT's affiliate paid the Subsidiary a non-refundable amount of $500 as a no-shop fee. The no-shop fee was deferred and the related revenue is recognized over the estimated term of the License Agreement.

For revenue recognition policy see note 1c.

Development and liquidity risks

The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Based on the Company’s current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond, although no assurance can be given that the Company will not need additional funds prior to such time. If there are unexpected increases in its operating expenses, the Company may need to seek additional financing during the next 12 months. Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, obtaining foreign regulatory approvals to sell its products internationally, or entering into licensing agreements with third parties. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Outstanding stock options, warrants and restricted stock units (“RSUs”) have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The weighted average number of common stock options, warrants and RSUs excluded from the calculation of diluted net loss was 4,366,806 and 4,352,798 for the three month periods ended November 30, 2019 and 2018, respectively.

Revenue recognition

The License Agreement and the SPA were considered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between the License Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock (less issuance expenses of $23), based on the quoted price of the Company's shares on the closing date of the SPA on December 28, 2015, and $38,883 was allocated to the License Agreement.

Under Accounting Standards Codification ("ASC") 605 (which was the authoritative revenue recognition guidance applied for all periods prior to September 1, 2018) given the Company's continuing involvement through the expected product submission in June 2023, amounts received relating to the License Agreement were recognized over the period from which the Company was entitled to the respective payment, and the expected product submission date using a time-based model approach over the periods that the fees were earned.

On September 1, 2018, the Company adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers (Topic 606)” (“ASC 606”), using the modified retrospective method of adoption. Under this method, the Company applied ASC 606 to the License Agreement at the adoption date and was required to make an adjustment to the September 1, 2018 opening accumulated deficit balance and all prior periods continue to be presented under ASC 605. The most significant impact from adopting ASC 606 was the impact of the timing of recognition of revenue associated with the milestone payment. Under ASC 605 (which was the authoritative revenue recognition guidance applied for all periods prior to September 1, 2018) given the Company's continuing involvement through the expected product submission in June 2023, amounts received relating to the License Agreement were recognized over the period from which the Company was entitled to the respective payment, and the expected product submission date using a time-based model approach over the periods that the fees were earned. However, under ASC 606, the Company is required to recognize the total transaction price (which includes consideration related to milestones once the criteria for recognition have been satisfied) using the input method over the period the performance obligation is fulfilled. Accordingly, once the consideration associated with a milestone is included in the transaction price, incremental revenue is recognized immediately based on the period of time that has elapsed towards complete satisfaction of the performance obligation. This method results in the recognition of revenue earlier than under ASC 605 and the resulting impact was recorded as a reduction of the opening balance of accumulated deficit at September 1, 2018 as further described below.

Under ASC 606, the Company identified a single performance obligation in the agreement and determined that the license and services are not distinct as the license and services are highly dependent on each other. In other words, HTIT cannot benefit from the license without the related services, and vice versa.

Since the customer benefits from the services as the entity performs, revenue is recognized over time through the expected product submission date in June 2023, using the input method. The Company used the input method to measure the process for the purpose of recognizing revenue, which approximates the straight line attribution. The Company used significant judgment when it determined the product submission date.

Under ASC 606, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. When assessing the portion, if any, of such milestones-related consideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the consideration related to milestones of which the occurrence is not considered the most likely outcome.

The Company then evaluates if any of the variable consideration determined in the first step is constrained by including in the transaction price variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company used significant judgment when it determined the first step of variable consideration.

The potential future royalty consideration is also considered a form of variable consideration under ASC 606 as it is based on a percentage of potential future sales of the Company's products. However, the Company applies the sales-based royalty exception and accordingly will recognize the sales-based royalty amounts when the related sale has occurred. To date, the Company has not recognized any royalty-related revenue.

As of the adoption date, the Company adjusted its accumulated deficit by $1,773 against contract liabilities due to the effect of variable consideration.

Amounts that were allocated to the License Agreement as of November 30, 2019 aggregated $22,382, all of which were received through the balance sheet date. Through November 30, 2019, the Company has recognized revenue associated with this agreement in the aggregate amount of $10,696 (of which $674 was recognized in the quarter ended November 30, 2019, and deferred the remaining amount of $11,686 which is presented as deferred revenues on the condensed consolidated balance sheet.

Financial instruments

In January 2016, the Financial Accounting Standards Board (“FASB”) issued guidance which updates certain aspects of recognition, measurement, presentation and disclosure of financial assets and financial liabilities (“ASU 2016-01”). The guidance requires entities to recognize changes in fair value in net income rather than in accumulated other comprehensive income. The Company adopted the provisions of this update in the first quarter of fiscal year 2019. Following the adoption, as of September 1, 2018, the Company classified the available for sale securities to financial assets measured in fair value through profit or loss. The impact of this adoption on the Company's accumulated losses as of the adoption date was $702.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and, except as described in note 1f, on the same basis as the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2019 (the “2019 Form 10-K”). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2019 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year’s results.

Recently adopted standards

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee’s income statement. The Company adopted this standard as of September 1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.

As of the adoption date, the Company recognized an operating lease asset and liability of $113 and $113, respectively, as of September 1, 2019 on its balance sheet.

Commitments

3 Months Ended

Nov. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

In March 2011, the Subsidiary sold shares of its investee company, Entera, to D.N.A, retaining 117,000 ordinary shares (after giving effect to a stock split by Entera in July 2018). In consideration for the shares sold to D.N.A, the Company received, among other payments, ordinary shares of D.N.A (see also note 4).

As part of this agreement, the Subsidiary entered into a patent transfer agreement (the "Patent Transfer Agreement") according to which the Subsidiary assigned to Entera all of its right, title and interest in and to a certain patent application related to the oral administration of proteins that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of November 30, 2019, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary. On December 11, 2018, Entera announced that it had entered into a research collaboration and license agreement (the "Amgen License") with Amgen related to research of inflammatory disease and other serious illnesses. As reported by Entera, under the terms of the Amgen License, Entera will receive a modest initial technology access fee from Amgen and will be responsible for preclinical development at Amgen's expense. Entera will be eligible to receive up to $270,000 in aggregate payments, as well as tiered royalties up to mid-single digits, upon achievement of various clinical and commercial milestones if Amgen decides to move all of these programs forward. Amgen is responsible for clinical development, manufacturing and commercialization of any of the resulting programs. To the extent the Amgen License results in net revenues as defined in the Patent Transfer Agreement, the Subsidiary will be entitled to the aforementioned royalties.

In addition, as part of a consulting agreement with a third party, dated February 15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royalties received in respect of the patent that was sold to Entera in March 2011.

On January 3, 2017, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 60 months commencing October 1, 2016.

The annual lease payment was New Israeli Shekel ("NIS") 119,000 ($32) from October 2016 through September 2018 and NIS 132,000 ($38) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index ("CPI") (as of November 30, 2019, the aggregate future lease payments will be $70 until the expiration of the lease agreement, based on the exchange rate as of November 30, 2019).

As security for its obligation under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On December 18, 2017, the Subsidiary entered into an agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $2,905 that will be paid over the term of the engagement and based on the achievement of certain development milestones, $1,542 of which was recognized in research and development expenses through November 30, 2019.

On February 14, 2018, the Subsidiary entered into a Clinical Research Organization Services Agreement with a third party, effective as of November 1, 2017, to retain it as a clinical research organization ("CRO") for the Subsidiary's three month dose-ranging clinical trial for its oral insulin capsule for type 2 diabetes patients and, on May 20, 2019, the Subsidiary entered into amendments to such agreement. As consideration for its services, the Subsidiary will pay the CRO a total amount of $10,206 during the term of the engagement and based on achievement of certain milestones, of which $8,003 was recognized in research and development expenses through November 30, 2019.

On May 21, 2018, the Subsidiary entered into a CRO Services Agreement with a third party to retain it as a CRO for the Subsidiary's food effect clinical trial for its oral insulin capsule. As consideration for its services, the Subsidiary will pay the CRO a total amount of $1,166 during the term of the engagement and based on achievement of certain milestones, $1,141 of which was recognized in research and development expenses through November 30, 2019.

On July 29, 2019, the Subsidiary entered into a CRO Services Agreement with a third party to retain it as a CRO for the Subsidiary's dose-ranging clinical trial for its oral insulin. As consideration for its services, the Subsidiary will pay the CRO a total amount of $658 during the term of the engagement and based on achievement of certain milestones, $313 of which was recognized in research and development expenses through November 30, 2019.

Grants from the Israel Innovation Authority ("IIA")

Under the terms of the Company's funding from the IIA, royalties of 3% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured. The total amount that was received through November 30, 2019 was $2,207.

The royalty expenses which are related to the funded project were recognized in cost of revenues in the quarter ended November 30, 2019 and in prior periods.

Grants from the European Commission ("EC")

On November 26, 2019 the Company received an initial payment of €17.50 from the EC under the SME Instrument of the European Innovation Programme Horizon 2020.

As part of the grant terms, the Company is required to use the proceeds from the grant in Europe. The Company intends on using the grant to explore the possibility of running clinical trials in Europe.

Fair Value

3 Months Ended

Nov. 30, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

The Company measures fair value and discloses fair value measurements for financial assets. Fair value is based on the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:	Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:	Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:	Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of November 30, 2019, the assets measured at fair value are comprised of equity securities (Level 1). The fair value of held to maturity bonds as presented in note 4 was based on a Level 2 measurement.

As of November 30, 2019, the carrying amounts of cash equivalents, short-term deposits and accounts payable approximate their fair values due to the short-term maturities of these instruments.

As of November 30, 2019, the carrying amounts of long-term deposits approximate their fair values due to the stated interest rates which approximate market rates.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

There were no Level 3 items for the three month periods ended November 30, 2019 and 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

3 Months Ended

Nov. 30, 2019

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES:

The Company's marketable securities include investments in equity securities of D.N.A and Entera, and in held to maturity bonds.

Composition:

	November 30, 2019		August 31, 2019
Short-term:
D.N.A (see b below)	$	296	$	557
Entera (see c below)		263		304
Held to maturity bonds (see d below)		2,648		2,840
	$	3,207	$	3,701
Long-term:
Held to maturity bonds (see d below)	$	250	$	1,295

D.N.A

The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

As of November 30, 2019, the Company owns approximately 6.9% of D.N.A's outstanding ordinary shares.

The cost of the securities as of November 30, 2019 and August 31, 2019 is $595.

Entera

Entera ordinary shares have been traded on The Nasdaq Capital Market since June 28, 2018. The Company measures the investment at fair value from such date, since it has a readily determinable fair value (prior to such date the investment was accounted for as a cost method investment (amounting to $1)).

Held to maturity securities

The amortized cost and estimated fair value of held-to-maturity securities as of November 30, 2019, are as follows:

	November 30, 2019
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	2,624	$	(16	)	$	2,608
Accrued interest		24		-			24

Long-term		250		-			250
	$	2,898	$	(16	)	$	2,882

As of November 30, 2019, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $250, and the yield to maturity rate is 2.77%.

The amortized cost and estimated fair value of held-to-maturity securities as of August 31, 2019, are as follows:

	August 31, 2019
	Amortized cost		Gross unrealized losses		Estimated fair value
Short-term:
Commercial bonds	$	2,808	$	6	$	2,814
Accrued interest		32		-		32

Long-term		1,295		4		1,299
	$	4,135	$	10	$	4,145

As of August 31, 2019, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $1,295 and the yield to maturity rates vary between 2.55% to 3.20%.

Held to maturity securities which will mature during the 12 months from the balance sheet date are included in short-term marketable securities. Held to maturity securities with maturity dates of more than one year are considered long-term marketable securities.

Stockholders' Equity

3 Months Ended

Nov. 30, 2019

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 5 - STOCKHOLDERS' EQUITY:

On September 5, 2019, the Company entered into an Equity Distribution Agreement (the "Sales Agreement"), pursuant to which the Company may, from time to time and at the Company's option, issue and sell shares of Company common stock having an aggregate offering price of up to $15,000, through a sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company's effective shelf registration statement on Form S-3 including a prospectus dated February 2, 2017, as supplemented by a prospectus supplement dated September 5, 2019. The Company will pay the sales agent a cash commission of 3.0% of the gross proceeds of the sale of any shares sold through the sales agent under the Sales Agreement. As of November 30, 2019, no shares were sold under the Sales Agreement. As of January 9, 2020, 335,163 shares were issued under the Sales Agreement for aggregate net proceeds of $1,785.

Related Parties - Transactions

3 Months Ended

Nov. 30, 2019

RELATED PARTIES - TRANSACTIONS

NOTE 6 - RELATED PARTIES - TRANSACTIONS:

On July 1, 2008, the Subsidiary entered into two consulting agreements with KNRY Ltd. ("KNRY"), an Israeli company owned by the Chief Scientific Officer (the "CSO"), whereby the Chief Executive Officer (the "CEO") and the CSO, through KNRY, provide services to the Company (the "Consulting Agreements"). The Consulting Agreements are both terminable by either party upon 140 days prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($37) and NIS 80,454 ($23), respectively.

In addition to the Consulting Agreements, based on a relocation cost analysis prepared by consulting company ORI - Organizational Resources International Ltd., the Company pays for certain direct costs, related taxes and expenses incurred in connection with the relocation of the CEO to New York. During the three months ended November 30, 2019, such relocation expenses totaled $86 compared to $131 for the three months ended November 30, 2018.

Significant Accounting Policies (Policies)

3 Months Ended

Nov. 30, 2019

Accounting Policies [Abstract]

General

General:

Incorporation and operations

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On July 30, 2019, the Subsidiary incorporated a wholly-owned subsidiary in Hong Kong, Oramed HK Limited. As of November 30, 2019, Oramed HK Limited has no operations.

The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions.

For revenue recognition policy see note 1c.

Development and liquidity risks

Loss per common share

Loss per common share

Revenue recognition

Revenue recognition

As of the adoption date, the Company adjusted its accumulated deficit by $1,773 against contract liabilities due to the effect of variable consideration.

Financial instruments

Financial instruments

Condensed Consolidated Financial Statements Preparation

Condensed Consolidated Financial Statements Preparation

Recently adopted standards

Recently adopted standards

As of the adoption date, the Company recognized an operating lease asset and liability of $113 and $113, respectively, as of September 1, 2019 on its balance sheet.

Marketable Securities (Tables)

3 Months Ended

Nov. 30, 2019

Investments, Debt and Equity Securities [Abstract]

Schedule of marketable securities include investments in equity securities

	November 30, 2019		August 31, 2019
Short-term:
D.N.A (see b below)	$	296	$	557
Entera (see c below)		263		304
Held to maturity bonds (see d below)		2,648		2,840
	$	3,207	$	3,701
Long-term:
Held to maturity bonds (see d below)	$	250	$	1,295

Schedule of amortized cost and estimated fair value of held-to-maturity securities

	November 30, 2019
	Amortized cost		Gross unrealized losses			Estimated fair value
Short-term:
Commercial bonds	$	2,624	$	(16	)	$	2,608
Accrued interest		24		-			24

Long-term		250		-			250
	$	2,898	$	(16	)	$	2,882

	August 31, 2019
	Amortized cost		Gross unrealized losses		Estimated fair value
Short-term:
Commercial bonds	$	2,808	$	6	$	2,814
Accrued interest		32		-		32

Long-term		1,295		4		1,299
	$	4,135	$	10	$	4,145

Significant Accounting Policies (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	Nov. 30, 2015	Dec. 28, 2015	Nov. 30, 2019	Nov. 30, 2018	Sep. 02, 2019	Aug. 31, 2019	Jul. 31, 2015
Significant Accounting Policies (Textual)
Milestone payment received			$ 20,500
Right of use assets and lease liabilities			106
License agreement value			22,382
Recognize revenue			10,696
Deferred costs			$ 11,686
Recognized revenue, description			Of which $674 was recognized in the quarter ended November 30, 2019.
Securities excluded from the calculation of diluted net loss			4,366,806	4,352,798
Non-refundable amount							$ 500
Milestone payment, description			The initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016, the fourth milestone payment of $4,000 was received in October 2016 and the fifth milestone payment of $3,000 was received in January 2019.
Reduction of accumulated deficit			$ 702
Accumulated deficit			(83,646)			$ (81,103)
Adjusted accumulated deficit against contract liabilities			1,773
Operating lease liability					$ 113
Operating lease Assets					$ 113
Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued ,value		$ 10,617
Total consideration		49,500
Issuance expenses		23
License Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued ,value		$ 38,883
Deferred costs			$ 11,686
HTIT [Member]
Significant Accounting Policies (Textual)
Percentages of royalties on net sales			10.00%
Aggregate license costs			$ 37,500
License costs payable			3,000
Amount paid subject to the Company entering into certain agreements			8,000
Payable upon achievement of certain milestones and conditions			$ 26,500
Royalty commitment description			In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.
Royalty term			15 years
HTIT [Member] \| Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued	1,155,367
Number of common stock issued ,value	$ 12,000

Commitments (Details) - USD ($) $ in Thousands		1 Months Ended					3 Months Ended
Commitments (Details) - USD ($) $ in Thousands	Dec. 11, 2018	Jul. 29, 2019	May 21, 2018	Feb. 14, 2018	Dec. 18, 2017	Mar. 31, 2011	Nov. 30, 2019	Oct. 01, 2016	Feb. 15, 2011
Commitments (Textual)
Total received							$ 2,207
Aggregate payments receive	$ 270,000
Grants from the European Commission, description							On November 26, 2019 the Company received an initial payment of €17.50 from the EC under the SME Instrument of the European Innovation Programme Horizon 2020.
Vendor One [Member]
Commitments (Textual)
Commitments for consulting services					$ 2,905
Expense which was recognized							$ 1,542
Vendor Two [Member]
Commitments (Textual)
Expense which was recognized							8,003
Vendor Three [Member]
Commitments (Textual)
Expense which was recognized							1,141
Vendor Four [Member]
Commitments (Textual)
Expense which was recognized							$ 313
Clinical Research Organization Services Agreement [Member]
Commitments (Textual)
Commitments for consulting services				$ 10,206
Office facilities [Member]
Commitments (Textual)
Operating lease, term								60 months
Lessee, description							The annual lease payment was New Israeli Shekel (“NIS”) 119,000 ($32) from October 2016 through September 2018 and NIS 132,000 ($38) from October 2018 through September 2021, and is linked to the increase in the Israeli consumer price index (“CPI”) (as of November 30, 2019, the aggregate future lease payments will be $70 until the expiration of the lease agreement, based on the exchange rate as of November 30, 2019).
Third party [Member] \| Clinical Research Organization Services Agreement [Member]
Commitments (Textual)
Commitments for consulting services		$ 658	$ 1,166
Entera Bio Ltd. [Member] \| D.N.A [Member]
Commitments (Textual)
Ownership percentage retained						3.00%			8.00%
Ordinary shares after stock split						117,000
Israel Innovation Authority [Member]
Commitments (Textual)
Royalty percentage							3.00%		8.00%
Israel Innovation Authority [Member] \| Minimum [Member]
Commitments (Textual)
Royalty percentage							100.00%
Israel Innovation Authority [Member] \| Maximum [Member]
Commitments (Textual)
Royalty percentage							150.00%

Marketable Securities (Details) - USD ($) $ in Thousands	Nov. 30, 2019	Aug. 31, 2019
Short-term:
D.N.A (see b below)	$ 296	$ 557
Entera (see c below)	263	304
Held to maturity bonds (see d below)	2,648	2,840
Marketable securities	3,207	3,701
Long-term:
Held to maturity bonds (see d below)	$ 250	$ 1,295

Marketable Securities (Details 1) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
Marketable Securities (Details 1) - USD ($) $ in Thousands	Nov. 30, 2019	Aug. 31, 2019
Summary of held to maturity securities [Abstract]
Amortized cost	$ 2,898	$ 4,135
Gross unrealized gains/losses	(16)	10
Estimated fair value	2,882	4,145
Short-term [Member] \| Accrued interest [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	24	32
Gross unrealized gains/losses
Estimated fair value	24	32
Long-term [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	250	1,295
Gross unrealized gains/losses		4
Estimated fair value	250	1,299
Commercial bonds [Member] \| Short-term [Member]
Summary of held to maturity securities [Abstract]
Amortized cost	2,624	2,808
Gross unrealized gains/losses	(16)	6
Estimated fair value	$ 2,608	$ 2,814

Marketable Securities (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Nov. 30, 2019	Aug. 31, 2019
Marketable Securities (Textual)
Percentage of ownership interest	6.90%
Cost of securities	$ 595	$ 595
Marketable securities	$ 250	$ 1,295
Yield to maturity rate	2.77%
Marketable securities maturity dates, description	After one year through two years.	After one year through two years.
Marketable securities maturity, term	12 months
Cost method investment	$ 1
Minimum [Member]
Marketable Securities (Textual)
Yield to maturity rate		2.55%
Maximum [Member]
Marketable Securities (Textual)
Yield to maturity rate		3.20%

Stockholders' Equity (Details) - Sales Agreement [Member] - USD ($) $ in Thousands		1 Months Ended
	Jan. 09, 2020	Sep. 05, 2019
Stockholders' Equity (Textual)
Common stock aggregate offering price		$ 15,000
Percentage of commission		3.00%
Subsequent Events [Member]
Stockholders' Equity (Textual)
Issuance of shares	335,163
Aggregate net proceeds	$ 1,785

Related Parties - Transactions (Details) ₪ in Thousands, $ in Thousands		3 Months Ended
	Jul. 01, 2008	Nov. 30, 2019 USD ($)	Nov. 30, 2019 ILS (₪)	Nov. 30, 2018 USD ($)
Relocation expenses \| $		$ 86		$ 131
KNRY [Member]
Consulting agreements, description	The Consulting Agreements are both terminable by either party upon 140 days prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($37) and NIS 80,454 ($23), respectively.
Chief Executive Officer [Member] \| NIS [Member]
Monthly consulting fee			₪ 127,570
Chief Scientific Officer [Member] \| NIS [Member]
Monthly consulting fee			₪ 80,454